Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidate...
May 15 2019 - 7:00AM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced
that they have entered into a research collaboration with ViiV
Healthcare, a global specialist HIV company established in November
of 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE)
dedicated to delivering advances in the treatment and care for
people living with HIV and for people who are at risk of becoming
infected with HIV, to evaluate the use of Matinas’ lipid
nano-crystal (“LNC”) platform delivery technology.
Formulations of select antivirals will be
developed using Matinas’ LNC platform delivery technology, which
enables the development of a wide range of difficult-to-deliver
molecules. Promising formulations will be tested in in vivo
preclinical studies to identify a lead LNC-antiviral formulation to
take forward in development.
“This is the second collaboration announced this
year where we have been asked to pair our LNC platform delivery
technology with molecules which could have a significant impact on
disease burden. In working closely with industry leading pharma
companies like ViiV, we are expanding the depth, breadth and
utilization of our disruptive platform and positioning our
technology to potentially solve complex issues related to
intracellular delivery in the absence of undesirable toxicity,”
said Jerome D. Jabbour, Chief Executive Officer of Matinas. “We
look forward to continuing to expand the application of our LNC
technology to potentially transformative medicines for the benefit
of patients in need.”
Matinas’ LNC platform delivery technology offers
an intracellular drug delivery solution with potential advantages
across a broad range of therapeutics. The Company has demonstrated
in preclinical animal models the ability to formulate and thereby
re-design a wide variety of molecules and drugs (including
oligonucleotides, peptides, proteins, vaccines, and small
molecules) which, (a) require delivery technology to improve the
stability of molecules inside and outside of the body; (b) could
benefit from efficient delivery and cellular uptake by target
cells; (c) are currently only available in IV formulations or (d)
otherwise experience significant toxicity-related adverse
events.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage
biopharmaceutical company focused on creating value through the
streamlined development of MAT9001 for the treatment of
cardiovascular and metabolic conditions and the application of its
lipid nano-crystal (“LNC”) platform technology to solve complex
challenges relating to the safe and effective delivery of small
molecules, gene therapies, proteins, peptides and vaccines.
The Company is actively pursuing the development
of MAT9001 with the support of a world-class team of clinical key
opinion leaders and regulatory consultants. MAT9001 is a
prescription-only omega-3 fatty acid-based composition, comprised
primarily of EPA and DPA, under development for
hypertriglyceridemia, which has shown superiority versus Vascepa®
(icosapent ethyl) in reducing serum triglycerides, Total- and
Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.
In addition, the Company's proprietary,
disruptive technology utilizes lipid nano-crystal cochleates to
encapsulate small molecules, nucleic acid polymers, vaccines and
other medicines potentially making them safer, more tolerable, less
toxic, and orally bioavailable.
For more information, please visit
www.matinasbiopharma.com and connect with the Company on Twitter,
LinkedIn and Facebook.
Matinas Forward-Looking
Statements: This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the Company's
strategic focus and the future development of its product
candidates, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the anticipated timing of
regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates, including MAT2203 and MAT9001; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to maintain and derive
benefit from the Qualified Infectious Disease Product (QIDP),
Orphan and/or Fast Track designations for MAT2203, which does not
change the standards for regulatory approval or guarantee
regulatory approval on an expedited basis, or at all; our ability
to protect the Company's intellectual property; the loss of any
executive officers or key personnel or consultants; competition;
changes in the regulatory landscape or the imposition of
regulations that affect the Company's products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma's
product candidates are all in a development stage and are not
available for sale or use.
Investor Contact Matinas
BioPharmaJenene ThomasJenene Thomas Communications,
LLCPhone: +1 (833) 475-8247Email: mtnb@jtcir.com
Source: Matinas BioPharma Holdings, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024